Back to Journals » International Journal of Nanomedicine » Volume 12

Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen

Authors Aliu H, Rask C, Brimnes J, Andresen TL

Received 14 March 2017

Accepted for publication 6 July 2017

Published 22 November 2017 Volume 2017:12 Pages 8377—8388

DOI https://doi.org/10.2147/IJN.S137033

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Thomas Webster


Have Aliu,1–3 Carola Rask,1 Jens Brimnes,1 Thomas Lars Andresen2,3

1Immunology Department, In vivo Biology Team, ALK Abelló A/S, Hørsholm, 2Department of Micro- and Nanotechnology, Technical University of Denmark, 3Center for Nanomedicine and Theranostics, Technical University of Denmark, Kgs Lyngby, Denmark

Abstract: Immunotherapy by sublingual administration of allergens provides high patient compliance and has emerged as an alternative to subcutaneous immunotherapy for the ­treatment of IgE-associated allergic diseases. However, sublingual immunotherapy (SLIT) can cause adverse events. Development of allergen delivery systems enabling more efficient delivery and hence lower allergen load might reduce the adverse events. In the present study, we have investigated neutral and cationic liposomes as delivery systems of ovalbumin (OVA), as a model allergen, in an OVA-induced allergic airway inflammation model. We investigated the liposome carriers’ ability to improve tolerance induction of antigens compared to the ­corresponding dose of free OVA. Mice were treated sublingually over 2 weeks with free or liposome encapsulated OVA followed by intraperitoneal injections and intranasal challenge. Mice sublingually treated with OVA-liposomes showed a significant reduction of airway eosinophilia and splenocyte proliferation in comparison to free OVA. A similar nonsignificant pattern was seen for OVA-specific IgE antibodies. In addition, reduced levels of interferon-γ and interleukin-5 were observed in spleen cell culture supernatants from OVA-liposome-treated mice compared to the sham-treated group. In conclusion, in vivo efficacy data showed that prophylactic SLIT with OVA-liposomes is significantly more effective in preventing allergic inflammation than the corresponding dose of free OVA.

Keywords: sublingual immunotherapy, drug delivery, allergy, liposome
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]